JP2021515588A5 - - Google Patents
Info
- Publication number
- JP2021515588A5 JP2021515588A5 JP2020560595A JP2020560595A JP2021515588A5 JP 2021515588 A5 JP2021515588 A5 JP 2021515588A5 JP 2020560595 A JP2020560595 A JP 2020560595A JP 2020560595 A JP2020560595 A JP 2020560595A JP 2021515588 A5 JP2021515588 A5 JP 2021515588A5
- Authority
- JP
- Japan
- Prior art keywords
- exchange protein
- cells
- target
- peptide exchange
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023213107A JP2024029012A (ja) | 2018-01-26 | 2023-12-18 | ペプチド交換蛋白質 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1801323.5A GB201801323D0 (en) | 2018-01-26 | 2018-01-26 | Peptide exchange protein |
| GB1801323.5 | 2018-01-26 | ||
| GB1813737.2 | 2018-08-23 | ||
| GBGB1813737.2A GB201813737D0 (en) | 2018-08-23 | 2018-08-23 | Peptide exchange protein |
| PCT/EP2019/051907 WO2019145509A1 (en) | 2018-01-26 | 2019-01-25 | Peptide exchange protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023213107A Division JP2024029012A (ja) | 2018-01-26 | 2023-12-18 | ペプチド交換蛋白質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515588A JP2021515588A (ja) | 2021-06-24 |
| JP2021515588A5 true JP2021515588A5 (https=) | 2022-01-19 |
Family
ID=65234583
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560595A Pending JP2021515588A (ja) | 2018-01-26 | 2019-01-25 | ペプチド交換蛋白質 |
| JP2023213107A Pending JP2024029012A (ja) | 2018-01-26 | 2023-12-18 | ペプチド交換蛋白質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023213107A Pending JP2024029012A (ja) | 2018-01-26 | 2023-12-18 | ペプチド交換蛋白質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12397036B2 (https=) |
| EP (1) | EP3743093A1 (https=) |
| JP (2) | JP2021515588A (https=) |
| CN (1) | CN111836635A (https=) |
| AU (1) | AU2019211121B2 (https=) |
| CA (1) | CA3089154A1 (https=) |
| WO (1) | WO2019145509A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11814420B2 (en) | 2018-07-06 | 2023-11-14 | The Regents Of The University Of California | Peptide deficient-MHC class I/chaperone compositions and methods |
| US20230059548A1 (en) * | 2020-01-03 | 2023-02-23 | The Regents Of The University Of California | Systems and methods for identification of mhc-i peptide epitopes |
| US12534510B2 (en) | 2020-04-16 | 2026-01-27 | The Regents Of The University Of California | Peptide-receptive MHC-I complex compositions and methods |
| US20250179143A1 (en) * | 2022-02-22 | 2025-06-05 | The Children's Hospital Of Philadelphia | Systems and methods for chaperone-mediated ligand exchange on mhc-i and mhc-related molecules using chicken tapbpr |
| WO2026024596A1 (en) * | 2024-07-22 | 2026-01-29 | The Children's Hospital Of Philadelphia | Methods of stimulating an immune response |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
| US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
| US5541104A (en) | 1991-05-23 | 1996-07-30 | Ludwig Institute For Cancer Research | Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 |
| JP3608788B2 (ja) | 1992-08-31 | 2005-01-12 | ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ | Ｍａｇｅ−３遺伝子から誘導されてｈｌａ−ａ１により提示される単離されたノナペプチドおよびそれらの用途 |
| US6222012B1 (en) | 1992-08-31 | 2001-04-24 | Ludwig Institute For Cancer Research | Isolated nonapeptides presented by HLA molecules, and uses thereof |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| CA2184482A1 (en) | 1994-03-01 | 1995-09-08 | Etienne De Plaen | Determination of cancerous conditions by mage gene expression |
| US6291430B1 (en) | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
| US7060479B2 (en) * | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
| US6692923B2 (en) * | 1999-04-14 | 2004-02-17 | Incyte Corporation | Tapasin-like protein |
| AU2001260847A1 (en) * | 2000-05-24 | 2001-12-03 | Genesis Research And Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
| EP1831370A4 (en) | 2004-12-13 | 2009-08-12 | Alethia Biotherapeutics Inc | POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN BONE RESOLUTION |
| EP2247309A4 (en) | 2008-01-28 | 2013-10-16 | Tapimmune Inc | TAPASINE REINFORCEMENT FOR AN IMPROVED IMMUNE RESPONSE |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| CN112851769A (zh) | 2014-01-27 | 2021-05-28 | 分子模板公司 | 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽 |
| CN107857819A (zh) * | 2017-07-03 | 2018-03-30 | 江苏西迪尔生物技术有限公司 | 多功能融合蛋白及其应用 |
| EP3820571A1 (en) | 2018-07-10 | 2021-05-19 | University of Connecticut | Reagents and methods for treating cancer and autoimmune disease |
-
2019
- 2019-01-25 CN CN201980018422.2A patent/CN111836635A/zh not_active Withdrawn
- 2019-01-25 JP JP2020560595A patent/JP2021515588A/ja active Pending
- 2019-01-25 AU AU2019211121A patent/AU2019211121B2/en active Active
- 2019-01-25 EP EP19701859.1A patent/EP3743093A1/en active Pending
- 2019-01-25 US US16/964,695 patent/US12397036B2/en active Active
- 2019-01-25 WO PCT/EP2019/051907 patent/WO2019145509A1/en not_active Ceased
- 2019-01-25 CA CA3089154A patent/CA3089154A1/en active Pending
-
2023
- 2023-12-18 JP JP2023213107A patent/JP2024029012A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021515588A5 (https=) | ||
| JP6321261B2 (ja) | ワクチン組成物及びその使用方法 | |
| Chen et al. | Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines | |
| US20240156953A1 (en) | Human herpesvirus immunotherapy | |
| Tindle et al. | A vaccine conjugate of ‘ISCAR’immunocarrier and peptide epitopes of the E7 cervical cancer‐associated protein of human papillomavirus type 16 elicits specific Th1‐and Th2‐type responses in immunized mice in the absence of oil‐based adjuvants | |
| KR20210021530A (ko) | 신규한 구조적 컴포넌트들을 갖는 나노입자 백신들 | |
| JP2013532971A5 (https=) | ||
| JP2021517813A5 (https=) | ||
| Kang et al. | Immunization with a self-assembled nanoparticle vaccine elicits potent neutralizing antibody responses against EBV infection | |
| Cho et al. | Design of immunogenic and effective multi-epitope DNA vaccines for melanoma | |
| Bazhan et al. | Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens | |
| Bazhan et al. | Rational design based synthetic polyepitope DNA vaccine for eliciting HIV-specific CD8+ T cell responses | |
| Baz et al. | Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses | |
| Xu et al. | Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine | |
| WO2022238363A1 (en) | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases | |
| Ramakrishna et al. | Codon optimization and ubiquitin conjugation of human immunodeficiency virus-1 Tat lead to enhanced cell-mediated immune responses | |
| Prathyusha et al. | Current advances in multi-epitope viral vaccines development and research | |
| Szécsi et al. | DNA vaccination with a single-plasmid construct coding for viruslike particles protects mice against infection with a highly pathogenic avian influenza A virus | |
| RU2626605C2 (ru) | Генетическая (рекомбинантная) ДНК-конструкция, содержащая кодон-оптимизированный ген гликопротеина (белка G) вируса бешенства с консенсусной аминокислотной последовательностью, которая составлена с учетом аминокислотных последовательностей белка G, выделяемого из штаммов вируса бешенства, циркулирующих на территории Российской Федерации | |
| AU2016201691B2 (en) | Vaccine compositions and methods of use thereof | |
| Nora et al. | Improved Tumor Specificity of Mesothelin (MSLN)-specific Killer Immunoglobulin Receptor (KIR)-based Chimeric Antigen Receptor (CAR) T cell therapy SynKIR-110 3562 | |
| CN110878126A (zh) | Tcr样嵌合抗原受体及其应用 | |
| Steinbuck et al. | Amphiphile-engineered DNA adjuvants stimulate strong type I IFN production in lymph nodes via cytosolic danger-sensing to induce potent cellular and humoral immunity in mice and non-human primates | |
| Cruz-Gomes | Harnessing the innate immune system for improved VLP-based immunotherapy | |
| Agrawal et al. | HETEROLOGOUS IMMUNITY: IMPLICATIONS AND APPLICATIONS IN VACCINES AND IMMUNOTHERAPIES |